CR20150639A - Derivados de benzimidazol como inhbidores de bromodominio - Google Patents

Derivados de benzimidazol como inhbidores de bromodominio

Info

Publication number
CR20150639A
CR20150639A CR20150639A CR20150639A CR20150639A CR 20150639 A CR20150639 A CR 20150639A CR 20150639 A CR20150639 A CR 20150639A CR 20150639 A CR20150639 A CR 20150639A CR 20150639 A CR20150639 A CR 20150639A
Authority
CR
Costa Rica
Prior art keywords
inhabitors
bromodominum
benzimidazol derivatives
compounds
bromodomain
Prior art date
Application number
CR20150639A
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Gregory Chin
Britton Kenneth Corkey
Jinfa Du
Kristyna Elbel
Robert H Jiang
Tetsuya Kobayashi
Rick Lee
Ruben Martinez
Samuel E Metobo
Michael Mish
Manuel Munoz
Sophie Shevick
David Sperandio
Hai Yang
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20150639A publication Critical patent/CR20150639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Esta solicitud se relaciona con compuestos químicos que pueden actuar como in-hibidores, o modular de alguna otra forma, la actividad de una proteína que con-tiene bromodominio, incluyendo la proteína 4 que contiene bromodominio (BRD4) y con composiciones y formulaciones que contienen dichos compuestos, así como métodos para usar y realizar dichos compuestos.
CR20150639A 2013-05-09 2015-12-04 Derivados de benzimidazol como inhbidores de bromodominio CR20150639A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361821612P 2013-05-09 2013-05-09
US201361826912P 2013-05-23 2013-05-23
US201361860229P 2013-07-30 2013-07-30
US201461951347P 2014-03-11 2014-03-11
PCT/US2014/037344 WO2014182929A1 (en) 2013-05-09 2014-05-08 Benzimidazole derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
CR20150639A true CR20150639A (es) 2016-01-29

Family

ID=50897952

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150639A CR20150639A (es) 2013-05-09 2015-12-04 Derivados de benzimidazol como inhbidores de bromodominio

Country Status (26)

Country Link
US (4) US20160075695A1 (es)
EP (1) EP2994469B1 (es)
JP (1) JP6049942B2 (es)
KR (1) KR101761049B1 (es)
CN (1) CN105324379B (es)
AP (1) AP2015008869A0 (es)
AR (1) AR096246A1 (es)
AU (1) AU2014262622B2 (es)
BR (1) BR112015028017A2 (es)
CA (1) CA2911408C (es)
CL (1) CL2015003280A1 (es)
CR (1) CR20150639A (es)
EA (1) EA029091B1 (es)
ES (1) ES2710120T3 (es)
HK (2) HK1219278A1 (es)
MD (1) MD4592B1 (es)
MX (1) MX2015015478A (es)
NZ (1) NZ713718A (es)
PE (1) PE20160029A1 (es)
PH (1) PH12015502534A1 (es)
PT (1) PT2994469T (es)
SG (1) SG11201509220XA (es)
TW (1) TWI527811B (es)
UA (1) UA112618C2 (es)
UY (1) UY35559A (es)
WO (1) WO2014182929A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
KR102355670B1 (ko) 2013-03-15 2022-02-08 인사이트 홀딩스 코포레이션 Bet 단백질 저해제로서의 삼환식 복소환
JP6461121B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． 新規の二環式ブロモドメイン阻害剤
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
ME03763B (me) 2014-04-23 2021-04-20 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina
EP3177604A1 (en) 2014-08-05 2017-06-14 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
US20190055235A1 (en) * 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
WO2016097863A1 (en) * 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN104788441A (zh) * 2015-04-02 2015-07-22 湖南华腾制药有限公司 一种多取代苯并恶唑衍生物的制备方法
GB201506658D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CA2985642A1 (en) * 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
CA2999253C (en) * 2015-09-21 2021-10-26 Plexxikon Inc. Heterocyclic compounds and uses thereof
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
CN108689945A (zh) * 2015-12-01 2018-10-23 江苏理工学院 一种苯并咪唑衍生物的制备方法
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US10316049B2 (en) 2015-12-17 2019-06-11 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
BR112018013063A2 (pt) * 2015-12-24 2018-12-11 Celgene Quanticel Res Inc combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
PE20190623A1 (es) 2016-06-20 2019-04-26 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
BR112018076821A2 (pt) 2016-06-24 2019-04-02 The Regents Of The University Of California derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
EP3532059B1 (en) 2016-10-27 2022-01-26 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097976A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
US20180153867A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
MX2019006821A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US11493520B2 (en) * 2017-05-19 2022-11-08 Epicypher, Inc. Assays for nucleosome remodeling activity
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
IL275478B1 (en) 2017-12-20 2024-02-01 Betta Pharmaceuticals Co Ltd A preparation that functions as a bromodomain protein inhibitor, and the composition
JP7062792B2 (ja) 2018-02-13 2022-05-06 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7337846B2 (ja) * 2018-05-08 2023-09-04 ボストン サイエンティフィック メディカル デバイス リミテッド 組織を穿刺するための装置及び方法
MX2020012137A (es) 2018-05-14 2021-01-29 Gilead Sciences Inc Inhibidores de mcl-1.
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
CN112399874B (zh) 2018-07-13 2024-03-22 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
CN113544129A (zh) * 2019-04-04 2021-10-22 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
PT2152701E (pt) 2007-03-12 2016-01-27 Ym Biosciences Australia Pty Compostos de fenil amino pirimidina e suas utilizações
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
EP2765860B1 (en) * 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Also Published As

Publication number Publication date
JP6049942B2 (ja) 2016-12-27
KR101761049B1 (ko) 2017-07-24
AU2014262622B2 (en) 2016-08-11
UA112618C2 (uk) 2016-09-26
HK1219278A1 (zh) 2017-03-31
EA029091B1 (ru) 2018-02-28
MD4592B1 (ro) 2018-09-30
HK1222646A1 (zh) 2017-07-07
AP2015008869A0 (en) 2015-11-30
US10017501B2 (en) 2018-07-10
MD20150121A2 (ro) 2016-05-31
PE20160029A1 (es) 2016-02-14
SG11201509220XA (en) 2015-12-30
AR096246A1 (es) 2015-12-16
TW201506022A (zh) 2015-02-16
CN105324379A (zh) 2016-02-10
NZ713718A (en) 2016-12-23
EP2994469A1 (en) 2016-03-16
JP2016520062A (ja) 2016-07-11
US9458145B2 (en) 2016-10-04
PH12015502534A1 (en) 2016-02-22
TWI527811B (zh) 2016-04-01
ES2710120T3 (es) 2019-04-23
CN105324379B (zh) 2018-12-04
WO2014182929A1 (en) 2014-11-13
KR20160008232A (ko) 2016-01-21
US20160075695A1 (en) 2016-03-17
CL2015003280A1 (es) 2016-06-24
MX2015015478A (es) 2016-06-14
EP2994469B1 (en) 2018-12-19
UY35559A (es) 2014-11-28
US20140336190A1 (en) 2014-11-13
BR112015028017A2 (pt) 2017-07-25
PT2994469T (pt) 2019-03-18
CA2911408A1 (en) 2014-11-13
AU2014262622A1 (en) 2015-11-12
CA2911408C (en) 2017-10-24
US20160376261A1 (en) 2016-12-29
EA201591965A1 (ru) 2016-08-31
US20180282316A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CR20150639A (es) Derivados de benzimidazol como inhbidores de bromodominio
CR20150515A (es) Derivados de bencimidazolona como inhibidores del bromodominio
CO2020007244A2 (es) Inhibidores de kras g12c
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CR20150066A (es) 2,3-benzodiacepinas
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CL2016000241A1 (es) Formulación de inhibidores de la syk.
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CO7461129A2 (es) Beta-glucosidasa de magnaporthe grisea
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
CL2015002060A1 (es) Compuestos.
GT201400090A (es) 2-tiopirimidinonas
UY34491A (es) La composición herbicida que contiene ácido de 4-amino-3-cloro-6- (4-cloro-2-flúor-3-metoxifenil) pyridina-2-carboxílico o los derivados de los mismos y fluroxipir o los derivados de los mismos
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4